Posted by Michael Wonder on 08 May 2018
Lynparza tablets receive EU approval for the treatment of platinum-sensitive relapsed ovarian cancer
8 May 2018 - New formulation reduces dosing to two tablets twice daily.
AstraZeneca and Merck today announced that the EMA has approved Lynparza (olaparib) tablets (300 mg twice daily) for use as a maintenance therapy for patients with platinum-sensitive relapsed high-grade, epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in complete response or partial response to platinum-based chemotherapy, regardless of BRCA status.
The EU approval was based on two randomised trials, SOLO-2 and Study 19, which showed that Lynparza reduced the risk of disease progression or death for platinum-sensitive relapsed ovarian cancer patients compared to placebo.
